Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials. The present studies mechanistically extended our initial observations. Low doses of sorafenib and vorinosta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Park, Margaret A., Zhang, Guo, Martin, Aditi Pandya, Hamed, Hossein, Mitchell, Clint, Hylemon, Philip B., Graf, Martin, Rahmani, Mohamed, Ryan, Kevin, Liu, Xiang, Spiegel, Sarah, Norris, James, Fisher, Paul B., Grant, Steven, Dent, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2674577/
https://ncbi.nlm.nih.gov/pubmed/18787411
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados